Analysis Avivagen, Inc. (VIVXF)
6/3/2024
Analysis of Avivagen, Inc. (VIVXF)
Avivagen, Inc. is currently trading at a price of 0.00120. The Relative Strength Index (RSI) indicator is at 17.33, indicating that the stock may be oversold. The Moving Average Convergence Divergence (MACD) indicator is -0.00093, with the MACD line below the signal line, suggesting a bearish trend.Looking at the moving averages, the Simple Moving Average (SMA) is at 0.00307, the Exponential Moving Average (EMA) is at 0.00264, and the Weighted Moving Average (WMA) is at 0.00237. All these moving averages are above the current price, indicating a bearish trend.
Overall, based on the technical indicators, Avivagen, Inc. is currently in a bearish trend with the stock being oversold. Traders and investors may want to exercise caution and further analyze the stock before making any trading decisions.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 2024. The company shows good returns on assets and equity.
Stock statistics show details such as short ratio, float shares, shares outstanding, and insider and institutional holdings. The company's stock price summary includes beta, moving averages, and the range of stock prices over the past fifty-two weeks.
Valuation metrics reveal information about the company's price-to-earnings ratios, enterprise value, price-to-book ratio, price-to-sales ratio, and market capitalization.
Lastly, dividends and splits data include details about payout ratio, dividend dates, split dates, dividend rates, and dividend yields.
Income statement 💸
Here are the revenue figures for the past four fiscal years:1. Fiscal Year 2023: Sales of $383,285,000,000
2. Fiscal Year 2022: Sales of $394,328,000,000
3. Fiscal Year 2021: Sales of $365,817,000,000
4. Fiscal Year 2020: Sales of $274,515,000,000
From these figures, we can observe the following trends:
- There was a decrease in sales from 2022 to 2023.
- Prior to 2023, there was a general increasing trend in sales over the years.
- The highest sales figure was recorded in 2022.
These trends can provide insights into the company's performance and market conditions over the years.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. Financing activities show significant fluctuations, especially in common stock repurchases and long-term debt issuuance.
5. Investing activities also vary, with notable amounts spent on the sale and purchase of investments.
6. The end cash position has been fluctuating, reaching its highest value in 2020 and its lowest in 2022.
These conclusions provide insights into the company's financial performance and management of cash flows over the years.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This is also an increase from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects growth compared to the EPS of $5.67 from the previous year.
4. For the next year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This indicates a potential increase from the EPS of $6.10 in the previous year.
Overall, the analysts' estimates suggest a positive outlook for the company's earnings per share, showing growth potential in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, showing a sales growth of 3% from the previous year's same quarter. There are 25 analysts contributing to these estimates.
3. Looking at the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, indicating a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates for the annual sales is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a significant sales growth of 6% compared to the current fiscal year. The number of analysts involved in forecasting the next year's sales is 38.
These estimates suggest a moderate but steady growth trend in both quarterly and annual sales for the company over the specified periods.
Growth estimates
Based on the consensus estimates provided:- The current year growth rate is estimated to be 7.6%
- The next quarter growth rate is estimated to be 5.1%
- The next year growth rate is estimated to be 9.7%
- The average annual growth rate for the next 5 years is estimated to be 9.7%
- The average annual growth rate for the past 5 years was 20.1%
It appears that the company is expected to experience a significant increase in growth compared to the past 5 years, with a particularly strong growth forecast for the next year. However, the growth rate is expected to moderate slightly over the next 5 years compared to the next year's estimate.
Price target
The analysts' forecast for the future price of the security paper is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security paper, with a median price of $201.43 and an average price of $204.58. However, it's worth noting that the current price is slightly lower at $192.25. Investors should consider these forecasts along with other factors when making investment decisions.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, from $323.9 billion in 2018 to $352.8 billion in 2023.
2. Current assets have fluctuated but generally increased, with the highest value in 2023 at $143.6 billion.
3. Non-current assets have also shown an increasing trend, reaching $209 billion in 2023.
4. Total liabilities have been increasing steadily, from $248 billion in 2019 to $290.4 billion in 2023.
5. Shareholders' equity has shown some fluctuations but has increased overall, from $90.5 billion in 2018 to $62.1 billion in 2023.
MACD of VIVXF
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
